Interplay between B7-H3 and HLA class I in the clinical course of pancreatic ductal adenocarcinoma

Cancer Lett. 2024 Apr 10:587:216713. doi: 10.1016/j.canlet.2024.216713. Epub 2024 Feb 14.

Abstract

Human leukocyte antigen (HLA) class I defects are associated with cancer progression. However, their prognostic significance is controversial and may be modulated by immune checkpoints. Here, we investigated whether the checkpoint B7-H3 modulates the relationship between HLA class I and pancreatic ductal adenocarcinoma (PDAC) prognosis. PDAC tumors were analyzed for the expression of B7-H3, HLA class I, HLA class II molecules, and for the presence of tumor-infiltrating immune cells. We observed defective HLA class I and HLA class II expressions in 75% and 59% of PDAC samples, respectively. HLA class I and B7-H3 expression were positively related at mRNA and protein level, potentially because of shared regulation by RELA, a sub-unit of NF-kB. High B7-H3 expression and low CD8+ T cell density were indicators of poor survival, while HLA class I was not. Defective HLA class I expression was associated with unfavorable survival only in patients with low B7-H3 expression. Favorable survival was observed only when HLA class I expression was high and B7-H3 expression low. Our results provide the rationale for targeting B7-H3 in patients with PDAC tumors displaying high HLA class I levels.

Keywords: B7–H3; HLA class I; NF-kB; PDAC; Tumor microenvironment.

MeSH terms

  • B7 Antigens / genetics
  • B7 Antigens / metabolism
  • B7-H1 Antigen / genetics
  • B7-H1 Antigen / metabolism
  • Carcinoma, Pancreatic Ductal* / pathology
  • Disease Progression
  • Histocompatibility Antigens Class I
  • Humans
  • Lymphocytes, Tumor-Infiltrating
  • Pancreatic Neoplasms* / metabolism
  • Prognosis

Substances

  • B7 Antigens
  • B7-H1 Antigen
  • Histocompatibility Antigens Class I
  • CD276 protein, human